Ann: Full Year Statutory Accounts and Appendix 4E, page-3

First 3 Last

Share
Profile

Follow
fishman67

4,209 Posts.

663

25/08/23

17:42

Post #: 69555757
Share

Originally posted by Footmax ↑

Cash for at least a year - but either a deal with HIV or a CR will have to occur in a years time - BIT should get over $1mil in R&D rebates in the interim.

Be nice to see some HIV trial data - hope it is good, but the delay is of some concern that maybe it is not definitive.

(e) Going concern
The financial statements have been prepared on a going concern basis which contemplates the realisation of assets and settlement of liabilities in the ordinary course of business. The Company has incurred a trading loss of $3,492,766 for the year ended 30 June 2023 and has accumulated losses of $55,263,766 at 30 June 2023. The Company has cash on hand of $3,984,387 at 30 June 2023 and used $3,290,035 of cash in operations for the year ended 30 June 2023 and received $1,430,725 in research and development government incentives. During the year ended 30 June 2023, the Company raised $6,000,731 before costs for the issue of shares and options. As at 30 June 2023, the Company had net assets of $3,172,656.
Theseconditions give rise to a material uncertainty that may cast significant doubtupon the Company’s ability to continue as a going concern. The ongoing operationof the Company is dependent on: x the Company raising additional funding fromshareholders or other parties; and/or x the Company reducing expenditure inline with available funding.
The directors have prepared cash flow projections that support the ability of the Company to continue as a going concern for the period 1 July 2023 to 31 August 2024. These cash flow projections include significant ongoing expenditure on research and development activities and assume the Company receives the research and development (‘R&D’ rebate from the Australian Government and maintains expenditure in line with available funding. In the event that the Company does not obtain additional funding and/or reduce expenditure in line with available funding, the achievement of which is significantly uncertain until secured or realised, it may not be able to continue its operations as a going concern and therefore may not be able to realise its assets and extinguish its liabilities in the ordinary course of operations and at the amounts stated in the financial statements.

Expand

3rd Quarter for the results SEPTEMBER!!! Next round of trials a PHASE 3……. Don’t think there be any issues raising funds lol

BIT Price at posting: 3.1¢ Sentiment: Buy Disclosure: Held
10 Upvote

0 Great analysis

Reply

Top Stories

SMI

Gold intercept of 8.6 g/t continues the positive storyline for Santana at NZ's RAS deposit

Earnings wrap Monday Week 34: A2 Milk, Bluescope, Suncorp's climate woes & more

Good habits matters when it comes to finances

NOX

Noxopharm aims for autoimmune market with first human trial of SOF-SKN

PR1

Fourfold skarn increase points the way to viable garnet project, says Pure

There are more pages in this discussion • 182 more messages in this thread...

First 3 Last

Add BIT (ASX) to my watchlist

(20min delay)
Last 2.7¢		Change 0.001(3.85%)		Mkt cap ! $24.36M

Open	High	Low	Value	Volume
2.7¢	2.8¢	2.6¢	$21.78K	807.4K

Buyers (Bids)

No.	Vol.	Price($)
2	138461	2.6¢

Sellers (Offers)

Price($)	Vol.	No.
2.7¢	194761	1

View Market Depth

No.	Vol.	Price($)
2	138461	0.026
10	880546	0.025
2	3373333	0.024
1	130000	0.023
4	825000	0.022

Price($)	Vol.	No.
0.027	194761	1
0.028	47808	2
0.029	260000	2
0.030	47636	2
0.031	159129	3

Last trade - 16.10pm 19/08/2024 (20 minute delay)

BIT (ASX) Chart

Ann: Full Year Statutory Accounts and Appendix 4E, page-3

Gold intercept of 8.6 g/t continues the positive storyline for Santana at NZ's RAS deposit

Earnings wrap Monday Week 34: A2 Milk, Bluescope, Suncorp's climate woes & more

Good habits matters when it comes to finances

Noxopharm aims for autoimmune market with first human trial of SOF-SKN

Fourfold skarn increase points the way to viable garnet project, says Pure

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Full Year Statutory Accounts and Appendix 4E, page-3

Top Stories

Gold intercept of 8.6 g/t continues the positive storyline for Santana at NZ's RAS deposit

Earnings wrap Monday Week 34: A2 Milk, Bluescope, Suncorp's climate woes & more

Good habits matters when it comes to finances

Noxopharm aims for autoimmune market with first human trial of SOF-SKN

Fourfold skarn increase points the way to viable garnet project, says Pure

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News